Geneediting method halts production of braindestroying proteins

first_img Email Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Click to view the privacy policy. Required fields are indicated by an asterisk (*) CHICAGO, ILLINOIS—Huntingtons disease, a neurological condition caused by brain-destroying mutant proteins, starts with mood swings and twitching and ends in dementia and death. The condition, which afflicts about 30,000 Americans, has no cure. But now, a new gene-editing method that many believe will lead to a Nobel Prize has been shown to effectively halt production of the defective proteins in mice, leading to hope that a potent therapy for Huntingtons is on the distant horizon.That new method is CRISPR, which uses RNA-guided enzymes to snip out or add segments of DNA to a cell. In the first time it has been applied to Huntingtons disease, CRISPR’s results are “remarkably encouraging,” says neuroscientist Nicole Déglon of the University of Lausanne in Switzerland, who led the mouse study, results of which she and her co-researcher Nicolas Merienne shared yesterday at the Society for Neuroscience Conference in Chicago, Illinois.As neurological diseases go, Huntingtons is an ideal candidate for CRISPR therapy, because the disease is determined by a single gene, Déglon notes. A mutation in the gene, which codes for a normally helpful brain protein called huntingtin, consists of different numbers of  “tandem repeats,” repeating segments of DNA that cause the protein to fold into a shape that is toxic to the brain. Déglon and her team wondered whether CRISPR could halt production of this dangerous molecule.center_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country Using a virus as a delivery vehicle, the researchers infected two separate groups of healthy adult mice with a mutant huntingtin gene, but only one group received the therapy: a CRISPR “cassette,” which includes DNA for the gene-editing enzyme Cas9 and the RNA to target the huntingtin gene. CRISPR-Cas9 works by “silencing” the part of the huntingtin gene that signals protein production. Researchers hypothesized that by cutting into these so-called “start sites,” they would be able to permanently pause synthesis of the huntingtin protein. If this were true, the mice treated with the CRISPR cassette would have little to no buildup of mutated proteins, and that’s exactly what Déglon and her team saw. After only 3 weeks, the two groups of mice showed a striking contrast: Those without the CRISPR treatment had large areas of protein aggregation, and those with the treatment had almost none—CRISPR’s editing had prevented nearly 90% of the rogue proteins. “Having reached about 90% [blockage of production] changes the story [of Huntingtons therapy] completely,” she says. “It opens new treatment strategies that are based in DNA, and so would have a permanent benefit for the rest of someone’s life.”Abdellatif Benraiss, a translational neuroscientist at the University of Rochester in New York who is not involved with the research, cautions that the current technique is not poised for that kind of longevity. Because CRISPR cannot yet discriminate between mutant and healthy huntingtin genes (a person typically has one of each and the targeted start site is the same for both copies), it essentially eliminates all huntingtin proteins, even the healthy variety.“If there is no specificity for mutant huntingtin, that’s a concern—this is not a treatment for 4 weeks or 4 months, this is going to be permanent,” he says. Though the role of healthy huntingtin proteins remains murky, they’re thought to be involved in basic cell functions such transporting materials and chemical signaling. “As bad as too much huntingtin is, we still need one copy [of its gene] so it can do its job in our bodies.”Déglon is already on the case. Her team plans next to use CRISPR to target individualized differences in the DNA sequences called single nucleotide polymorphisms (SNPs). In many cases, these SNPS are located right next to the mutation on a DNA sequence, effectively flagging it for researchers. Combined with this SNP differentiation, the researchers plan to test the CRISPR-Cas9 treatment in “humanized” mice—mice that, instead of carrying the mouse version of mutant huntingtin, carry two copies of the human gene, one mutant and one healthy. That approach would bring the model closer to how this kind of a CRISPR treatment may act in humans.  “We’re just at the beginning of the story,” Déglon says. “There are still many questions to ask, unfortunately.” She pauses and then brightens, “Well, actually, fortunately, too.”last_img

Tags: , , , , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Comments